Literature DB >> 27611862

IL-7/IL-7 receptor axis stimulates prostate cancer cell invasion and migration via AKT/NF-κB pathway.

Hu Qu1, Zihao Zou2, Zhaojun Pan2, Tianwei Zhang2, Nan Deng2, Guoxi Chen2, Zhongyang Wang3.   

Abstract

IL-7, acting via IL-7 receptor (IL-7R), plays an important role in tumor progression. Elevated IL-7 expression has been reported to be observed in prostate cancer tissues and closely associated with poor prognosis. However, the biological functions of IL-7 and its receptor in prostate cancer cell invasiveness remain unclear. In our study, we found that the expressions of IL-7 and IL-7R were both upregulated in prostate cancer cells. IL-7 dose-dependently promoted the invasion and migration of prostate cancer cells, whereas knockdown of IL-7R attenuated the effect of IL-7. Further, IL-7/IL-7R axis induced the activation of AKT and NF-κB, whereas blocking of AKT suppressed IL-7-mediated NF-κB activity. Moreover, IL-7/IL-7R axis increased MMP-3 and MMP-7 expression of prostate cancer cells, whereas inhibition of NF-κB as well as MMPs activity suppressed IL-7-mediated cell invasion and migration. Together, these data identify IL-7/IL-7R axis to be involved in prostate cancer cell invasion and migration, probably via activating AKT/NF-κB pathway and upregulating MMP-3 and MMP-7 expression. Therefore, blocking IL-7/IL-7R axis may provide a potential therapeutic strategy to treat prostate cancer.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AKT; IL-7; IL-7R; Invasion; NF-κB; Prostate cancer

Mesh:

Substances:

Year:  2016        PMID: 27611862     DOI: 10.1016/j.intimp.2016.08.017

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  15 in total

1.  Interplay between immune cells in lung cancer: beyond T lymphocytes.

Authors:  Juan-Manuel Hernandez-Martinez; Edgar Vergara; Edgar Montes-Servín; Oscar Arrieta
Journal:  Transl Lung Cancer Res       Date:  2018-12

Review 2.  Flip the coin: IL-7 and IL-7R in health and disease.

Authors:  João T Barata; Scott K Durum; Benedict Seddon
Journal:  Nat Immunol       Date:  2019-11-19       Impact factor: 25.606

3.  Interleukin (IL)-7 Signaling in the Tumor Microenvironment.

Authors:  Iwona Bednarz-Misa; Mariusz A Bromke; Małgorzata Krzystek-Korpacka
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Withaferin A Inhibits Prostate Carcinogenesis in a PTEN-deficient Mouse Model of Prostate Cancer.

Authors:  Jim Moselhy; Suman Suman; Mohammed Alghamdi; Balaji Chandarasekharan; Trinath P Das; Alatassi Houda; Murali Ankem; Chendil Damodaran
Journal:  Neoplasia       Date:  2017-05-07       Impact factor: 5.715

5.  Analysis of aqueous humor concentrations of cytokines in retinoblastoma.

Authors:  Yong Cheng; Shufeng Zheng; Chung-Ting Pan; Mengke Yuan; Libin Chang; Yuou Yao; Mingwei Zhao; Jianhong Liang
Journal:  PLoS One       Date:  2017-05-09       Impact factor: 3.240

6.  miR-200a contributes to the migration of BMSCs induced by the secretions of E. faecalis via FOXJ1/NFκB/MMPs axis.

Authors:  Mingwei Li; Lifan Wei; Wei Zhou; Zhiyan He; Shujun Ran; Jingping Liang
Journal:  Stem Cell Res Ther       Date:  2020-07-25       Impact factor: 6.832

Review 7.  Cytokines and Chemokines as Mediators of Prostate Cancer Metastasis.

Authors:  Timothy O Adekoya; Ricardo M Richardson
Journal:  Int J Mol Sci       Date:  2020-06-23       Impact factor: 5.923

8.  Identification of candidate miRNAs in early-onset and late-onset prostate cancer by network analysis.

Authors:  Rafael Parra-Medina; Liliana López-Kleine; Sandra Ramírez-Clavijo; César Payán-Gómez
Journal:  Sci Rep       Date:  2020-07-23       Impact factor: 4.379

9.  Genetic polymorphisms in IL-7 and IL-7R are correlated with lung cancer risk in the Chinese Han population.

Authors:  Chan Zhang; Pincan Su; Wanlu Chen; Qi Li; Run Dai; YuJing Cheng; Jiangcun Yang
Journal:  Cancer Manag Res       Date:  2019-06-11       Impact factor: 3.989

Review 10.  Mevalonate Metabolism in Cancer Stemness and Trained Immunity.

Authors:  Georg Gruenbacher; Martin Thurnher
Journal:  Front Oncol       Date:  2018-09-20       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.